IRCT2013030512398N3已完成3 期
A Randomized, Double-blind Controlled Study to Determine the Effectiveness, Safety and Tolerability of Actorif® Compared to Rebif® in Subjects with Relapsing Remitting Multiple Sclerosis (RRMS)
Biosun Pharmed Company0 个研究点目标入组 144 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 144
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 55 years（—）
- 性别
- All
入选标准
- •Inclusion Criteria:
- •Male or female patients aged between 18-55 years, with a diagnosis of RRMS based on McDonald criteria 2010and or have two relapses in previous two years, and are eligible for interferon beta 1a therapy according to indications and clinical use in the product monograph; Patients must have an EDSS score of 0.0 to 5.5;Patients must have at least 2 relapses in previous 2 years; Signed informed consent obtained prior to initiation the study; Patients do not have any condition that mandates excluding them from the study; Female patients of child-bearing potential must have a negative pregnancy test and use at least one form of contraception as approved by the Investigator for four weeks prior to the study and during the study. For the purposes of this study, child-bearing potential is defined as: All female patients unless they are post-menopausal for at least one year or are surgically sterile”; Ability to co-operate with the treatment and follow up.
- •Exclusion Criteria
- •Disease-dependent criteria(Participant has an ongoing MS relapse; Has any progressive form of MS;Presenting MS relapse within 30 days prior to study drug administration); Safety of treatment dependent criteria: Presence of any serious concomitant systemic disorders incompatible with the administration of interferon beta-1a or any systemic disease that can influence the patient's safety(history of hypersensitivity to natural or recombinant interferon beta-1a, or hypersensitivity to human albumin or any other component of the formulation; History of uncontrolled seizures within the 3 months prior to enrollment; History of suicidal ideation or an episode of severe depression within the 3 months prior to enrollment; Serious local infection or systemic infection within 8 weeks prior to enrollment; Pregnant or breast-feeding patients or any patient with childbearing potential not using adequate contraception; History of major depression; History of major cardiac disease; History of known malignancy(except: S.C.C,B.C.C, non melanoma) or patient who is under chemotherapy); Patients with inadequate organ function(Bone Marrow: absolute neutrophil count (ANC) = 1.5 x 109/L, platelet count =100 x 109/L,Hemoglobin = 9 g/dL; Hepatic: Bilirubin = 1.5 x the upper limit of normal (ULN),aspartate transaminases (AST/SGOT) And/or alkaline transaminases(ALT/SGPT)=2.5xULN,alkaline phosphatase (AP)=2.5 x ULN; Renal: Serum creatinine =1.5 mg/dL or creatinine clearance = 60 mL/min calculated according to the Cockroft and Gault formula); Criteria dependent on compliance with study procedures, or the evaluation of the disability(Unwilling to use a reliable and acceptable contraceptive method throughout the study period;Conditions interfering with Magnetic Resonance Imaging (MRI) or Gadolinium DTPA (Gadovist, contrast agent) allergy or Inability to undergo MRI with gadolinium administration;Treatment with certain other agents to treat MS underlying disease; Participant received any other approved disease modifying therapy for MS (e.g. glatiramer acetate IV, Immunoglobulin, Azathriopine, Methotrexate, Cyclophosphamide, Mitoxantrona, Plasmapheresis) or any cytokine or anti-cytokine therapy within the 3 months prior to Study Day 0 (SD0);Systemic corticosteroids within 30 days prior to the initiation of this study treatment;Treatment with any investigational product within 30 days prior to study drug administration; Previous participation in this study.)
排除标准
- 未提供
研究者
相似试验
已完成
3 期
The Effectiveness, Safety and Tolerability of Actovex® Compared to Avonex® in Subjects with Relapsing Remitting Multiple Sclerosis (RRMS)Comparative interventional IFN.ß-1a treatment in Relapsing Remitting Multiple Sclerosis (RRMS).Multiple SclerosisIRCT2013020812398N1Actover Pharmaceutical company138
已完成
3 期
The Effectiveness, Safety and Tolerability of Actoferon® Compared to Betaferon® in Subjects with Relapsing Remitting Multiple Sclerosis (RRMS)Comparative interventional IFN.ß-1b treatment in Relapsing Remitting Multiple Sclerosis (RRMS).Multiple SclerosisIRCT2013030512398N2Actover Pharmaceutical company140
已完成
不适用
COlchicine for the preVention of postopErative atrial fibRillation in patients undergoing Coronary Artery By-pass GraftingCoronary Artery Disease ? Coronary Artery Surgery ? Atrial FibrillationCirculatory SystemAtherosclerotic heart diseaseISRCTN72835417Catholic University of the Sacred Heart-Rome (Italy)320
进行中（未招募）
1 期
GP2013 in the Treatment of RA Patients Refractory to or Intolerant of Standard TherapyEUCTR2010-021184-32-HUHexal AG124
进行中（未招募）
1 期
GP2013 in the Treatment of RA Patients Refractory to or Intolerant of Standard TherapyRefractory rheumatoid arthritisMedDRA version: 18.0Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2010-021184-32-EEHexal AG312